[4]Mosnier A., Caini S., Daviaud I. Clinical characteristics are similar across type A and B influenza virus infections. PLoS One. 2015;10:e0136186. 9
[5]Belongia E.A., Simpson M.D., King J.P. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16:942-951. 8
[6]Schild G.C., Oxford J.S., de Jong J.C., Webster R.G. Evidence for host-cell selection of influenza virus antigenic variants. Nature. 1983;303:706-709.
[7]Zost S.J., Parkhouse K., Gumina M.E. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017;114:12578-12583. 47
[8]Houser K., Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17:295-300. 3